Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CDNA

CDNA - CareDx Inc Stock Price, Fair Value and News

$20.46-0.12 (-0.58%)
Market Closed

69/100

CDNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

69/100

CDNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$25.2

Target 3M

$21.52

Target 6M

$22.69

CDNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDNA Price Action

Last 7 days

-1.8%

Last 30 days

6.6%

Last 90 days

41.4%

Trailing 12 Months

-10.4%

CDNA RSI Chart

CDNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDNA Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

14.94

Price/Sales (Trailing)

2.94

EV/EBITDA

11.3

Price/Free Cashflow

24.73

CDNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$25.2

Target 3M

$21.52

Target 6M

$22.69

CDNA Fundamentals

CDNA Revenue

Revenue (TTM)

358.0M

Rev. Growth (Yr)

20.72%

Rev. Growth (Qtr)

15.43%

CDNA Earnings

Earnings (TTM)

70.5M

Earnings Growth (Yr)

115.75%

Earnings Growth (Qtr)

119.55%

CDNA Profitability

Operating Margin

85.58%

EBT Margin

19.71%

Return on Equity

22.64%

Return on Assets

16.3%

Free Cashflow Yield

4.04%

CDNA Investor Care

Buy Backs (1Y)

4.10%

Diluted EPS (TTM)

1.28

CDNA Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025346.4M340.8M358.0M0
2024275.1M297.1M312.8M333.8M
2023319.6M309.3M297.1M280.3M
2022308.4M314.9M318.6M321.8M
2021221.2M253.6M275.8M296.4M
2020139.5M149.8M169.4M192.2M
201988.5M102.1M114.8M127.1M
201850.8M56.6M65.6M76.6M
201745.7M47.0M46.7M48.3M
201627.5M31.1M36.4M40.6M
201528.6M29.0M29.4M28.1M
201423.0M24.4M25.2M27.3M
201320.9M21.3M21.7M22.1M
201200020.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About CareDx Inc

CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEcaredx.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES727

CareDx Inc Frequently Asked Questions

CDNA is the stock ticker symbol of CareDx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of CareDx Inc is 1.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CDNA's fair value in chart for subscribers.

The fair value guage provides a quick view whether CDNA is over valued or under valued. Whether CareDx Inc is cheap or expensive depends on the assumptions which impact CareDx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDNA.

As of Wed Jan 28 2026, CDNA's PE ratio (Price to Earnings) is 14.94 and Price to Sales (PS) ratio is 2.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDNA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, CareDx Inc has provided 0.154 (multiply by 100 for percentage) rate of return.